NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ('LB Pharmaceuticals” or the 'Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on July 10, 2026, pursuant to the 'inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Zergebel entering into employment with LB Pharmaceuticals.